DBV Technologies still expects to receive an FDA decision in early August for its peanut allergy patch. But on Friday the company, which is headquartered in the southern outskirts of Paris, said it would start layoffs and scale down its drug development activities to save cash in case the radio silence it says it has received from the agency since it submitted additional data in April indicates further delays to come.
Once the company was vying with Aimmune Therapeutics (NASDAQ: AIMT) to win the first regulatory OK for a food allergy immunotherapy. In January, Aimmune’s drug, Palforzia, beat DBV’s… Read more »
UNDERWRITERS AND PARTNERS
